Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
about
Therapeutic options in peripheral T cell lymphomaAdvancement in high dose therapy and autologous stem cell rescue in lymphomaConsolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspectiveEnteropathy-Associated T-Cell Lymphoma.Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyOutcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphomaToward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaThe role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaComparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyRate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations.New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.How I treat the peripheral T-cell lymphomasRomidepsin for the Treatment of Peripheral T-Cell Lymphoma.Surgery in (pre)malignant celiac disease.Type I enteropathy-associated T-cell lymphoma in the colon of a 29-year-old patient and a brief literature review.Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and managementCurrent Biosafety Considerations in Stem Cell Therapy.CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.Novel therapies for peripheral T-cell lymphomas.Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.Romidepsin for peripheral T-cell lymphoma.
P2860
Q26748857-4F476C16-57A4-426E-9AB7-C7C0F84185AFQ26795538-6087AC95-DA6D-4A3E-843B-77331797312AQ26998446-04C9FB5E-942B-4821-844F-31D95931F80CQ30239728-CCCA6D94-BFA5-4726-AF31-6E3456F93CFFQ30613674-81BEFE83-A5C7-49CB-BCCD-BD382FB0CB8BQ30895580-F1AB9C91-19C1-4742-9CDA-F0522F922DCBQ31092020-ECBDE409-2FEC-4611-8ED3-8DDB1AACE598Q33408536-83161E38-4CC5-4089-89A1-DDC3CE5F3EDEQ33425087-C72B1B5C-4904-4E77-9D35-82A9B94086B8Q33428066-8B2C7CC3-B741-4AE9-A448-91BA18F7ECB4Q33431457-9D035719-804D-45CD-B7D8-B0BBDCC29A1FQ33434137-E7A9A2C3-DA44-4320-8A41-3BF4722CFB7AQ33608520-28704229-6077-4CD2-BE7C-16D22C061E27Q33670421-E210AAD5-4E6C-4B01-A2B8-B4ADA98ECBE8Q33702181-10A44F08-8176-48A5-A5D8-C3BB73BA9D86Q33824082-296134CA-649B-4642-A7A0-6B0523B1FD3FQ34034389-79F82F24-13EC-4557-9601-57BA0C85EFCFQ34106853-53B40483-35C4-48F0-9C11-CCB4E9081167Q34226010-51B1EC8D-BBAD-4B78-AE7B-A47D4ADDCA66Q34257135-8073ADC8-FE28-4D50-8F6B-585CB9DA8863Q35025993-1BFE94B2-58B9-45AE-A5B6-AE127B44E805Q35224833-8AACDA55-7BA2-4944-BAB7-B65B54565AA8Q35533531-CD8CBA48-DB1C-49C3-8359-EB2E6BA6D3F5Q35586880-7F61F191-AC5F-4A16-9D83-368040517ADCQ35697053-47A4AEBD-11CF-4D36-8D76-32F5369C83B7Q35703714-1BE27863-5218-4371-8D4A-E55A39221971Q35865090-E0E4A26D-C9D7-4B6D-B921-AFBA0D88F4A8Q36064937-6DE1A179-430C-43B4-A929-ADDF4457BBE7Q36290402-B36C092A-C327-4B4E-B9E5-1C8FA4B67D79Q36623655-17AD31E1-1941-44B0-BC20-8C0F5704C91DQ36907048-DCF121BD-B365-4BD5-9F36-65FFE9E23056Q36926529-CA235695-0057-4319-BF43-07FA1ECA1A4FQ37183239-6B24375F-0BAA-4B25-A130-972784AE8EC4Q37214534-1A9CDE12-311E-4F64-87AD-557A6A196AF1Q37271019-C9E3C9DE-A376-415A-B158-069FBA95338EQ37391571-57066299-1F8A-493A-8AC7-7B8A1BC82C29Q37606643-C8F738C4-814B-49BC-A35A-8C531E6AB3F0Q38111388-395C98E8-269B-4989-BB35-D886336B9324Q38113568-9AA123B2-3E94-4516-96F6-BA754F21DB5EQ38132813-FC313CC8-43BF-44A5-9FAF-32A872FC141E
P2860
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
description
im September 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2012
@uk
name
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@en
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@nl
type
label
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@en
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@nl
prefLabel
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@en
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@nl
P2093
P356
P1476
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
@en
P2093
Anders Österborg
Bjørn Østenstad
Christer Sundström
Elisabeth Ralfkiaer
Esa Jantunen
Francesco d'Amore
Grete F. Lauritzsen
Hans Hagberg
Harald Anderson
Harald Holte
P304
P356
10.1200/JCO.2011.40.2719
P407
P50
P577
2012-09-01T00:00:00Z